These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 12708501)

  • 1. Molecular targeting therapy for cancer: the Twelfth International Symposium of the Hiroshima Cancer Seminar, November 2002.
    Yasui W; Nishiyama M; Tsuruo T; Tahara E
    Cancer Sci; 2003 Feb; 94(2):221-3. PubMed ID: 12708501
    [No Abstract]   [Full Text] [Related]  

  • 2. [New therapeutic targets and strategies in lung cancer].
    Sánchez De Cos Escuín J
    Arch Bronconeumol; 2002 Aug; 38(8):386-91. PubMed ID: 12199921
    [No Abstract]   [Full Text] [Related]  

  • 3. Farnesyltransferase inhibitors.
    Adjei AA
    Cancer Chemother Biol Response Modif; 2005; 22():123-33. PubMed ID: 16110610
    [No Abstract]   [Full Text] [Related]  

  • 4. From bench top to bedside.
    Barinaga M
    Science; 1997 Nov; 278(5340):1036-9. PubMed ID: 9381201
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical trials referral resource. Clinical trials with the farnesyl transferase inhibitor R115777.
    Wright J; Blatner GL; Cheson BD
    Oncology (Williston Park); 1999 Nov; 13(11):1527, 1530, 1533. PubMed ID: 10581601
    [No Abstract]   [Full Text] [Related]  

  • 6. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing targeted therapies for lung cancer.
    Gandara DR
    Clin Adv Hematol Oncol; 2003 Nov; 1(11):648-9, 690. PubMed ID: 16258461
    [No Abstract]   [Full Text] [Related]  

  • 8. Farnesyltransferase inhibitors in breast cancer therapy.
    Dy GK; Adjei AA
    Cancer Invest; 2002; 20 Suppl 2():30-7. PubMed ID: 12442347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Farnesyltransferase inhibitors.
    Kurzrock R
    Clin Adv Hematol Oncol; 2005 Mar; 3(3):161-2. PubMed ID: 16166986
    [No Abstract]   [Full Text] [Related]  

  • 10. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM; Hamilton AD
    Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors of farnesyltransferase: a rational approach to cancer chemotherapy?
    Bell IM
    J Med Chem; 2004 Apr; 47(8):1869-78. PubMed ID: 15055985
    [No Abstract]   [Full Text] [Related]  

  • 12. Preclinical and clinical evaluation of farnesyltransferase inhibitors.
    Baum C; Kirschmeier P
    Curr Oncol Rep; 2003 Mar; 5(2):99-107. PubMed ID: 12583826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Farnesyltransferase inhibitors: targeting the molecular basis of cancer.
    Oliff A
    Biochim Biophys Acta; 1999 May; 1423(3):C19-30. PubMed ID: 10382537
    [No Abstract]   [Full Text] [Related]  

  • 14. Farnesyltransferase inhibitors.
    Adjei AA
    Cancer Chemother Biol Response Modif; 2003; 21():127-44. PubMed ID: 15338743
    [No Abstract]   [Full Text] [Related]  

  • 15. Novel targeted agents in the treatment of lung cancer.
    Saba N; Khuri F
    Expert Opin Investig Drugs; 2004 Jun; 13(6):609-29. PubMed ID: 15174948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Farnesyltransferase inhibitors.
    Hahn SM; Bernhard E; McKenna WG
    Semin Oncol; 2001 Oct; 28(5 Suppl 16):86-93. PubMed ID: 11706400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A selective ATP-binding cassette subfamily G member 2 efflux inhibitor revealed via high-throughput flow cytometry.
    Strouse JJ; Ivnitski-Steele I; Khawaja HM; Perez D; Ricci J; Yao T; Weiner WS; Schroeder CE; Simpson DS; Maki BE; Li K; Golden JE; Foutz TD; Waller A; Evangelisti AM; Young SM; Chavez SE; Garcia MJ; Ursu O; Bologa CG; Carter MB; Salas VM; Gouveia K; Tegos GP; Oprea TI; Edwards BS; Aubé J; Larson RS; Sklar LA
    J Biomol Screen; 2013 Jan; 18(1):26-38. PubMed ID: 22923785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives.
    Binkhathlan Z; Lavasanifar A
    Curr Cancer Drug Targets; 2013 Mar; 13(3):326-46. PubMed ID: 23369096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical reversal of multidrug resistance.
    Sikic BI; Fisher GA; Lum BL; Brophy NA; Yahanda AM; Adler KM; Halsey J
    Cancer Treat Res; 1994; 73():149-65. PubMed ID: 7710904
    [No Abstract]   [Full Text] [Related]  

  • 20. RAS inhibitors: potential for cancer therapeutics.
    Kloog Y; Cox AD
    Mol Med Today; 2000 Oct; 6(10):398-402. PubMed ID: 11006529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.